GENE - ジェネティック・テクノロジ―ズ (Genetic Technologies Ltd) ジェネティック・テクノロジ―ズ

 GENEのチャート


 GENEの企業情報

symbol GENE
会社名 Genetic Technologies Ltd. (ジェネティック・テクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ジェネティック・テクノロジズ(Genetic Technologies Limited)は診断製品事業に従事している。同社は遺伝子テストを製品・サービスに変換している。同社の癌診断事業は製品及びサービスの持続的な安定性を構築することに集中している。同社は、癌診断を含む遺伝子テスト事業、ライセンス事業及び研究事業という3つの事業区分を通して運営している。「BREVAGen」は指導予防治療法または先端監視決定であり、女性向けにパーソナライズされた遺伝学に基づくリスクスコアを提供している。同社の顧客は主に臨床医である。同社の海外子会社5社には、Gtech International Resources Limited、Genetic Technologies (Beijing) Limited、GeneType AG、GeneType Corporation及びPhenogen Sciences Incが含まれている。平成22年4月、同社は非家族性乳癌リスク評価テスト「BREVAGen」を含むPerlegen Sciences Inc.の資産を買収した。   ジェネティック・テクノロジ―ズは、遺伝子研究や検査に従事するオ―ストラリアのバイオテクノロジ―企業。DNA分析、犯罪現場捜査、血清学、民事及び刑事犯罪の鑑定人やコンサルティングサ―ビスなどを専門とする法医学バイオ技術を提供。オ―ストラリア、中国カナダ、スイス、米国で事業を展開。   
本社所在地 60-66 Hanover Street Fitzroy Melbourne Victoria 3065 AUS
代表者氏名 Paul Alexander Kasian ポールアレクサンダーカシアン
代表者役職名 Non-Executive Chairman of the Board Acting Chief Executive Officer
電話番号 +61 3-9415-1135
設立年月日 31778
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数
url www.gtglabs.com
nasdaq_url https://www.nasdaq.com/symbol/gene
adr_tso 10706141
EBITDA EBITDA(百万ドル) -4.73309
終値(lastsale) 1.07
時価総額(marketcap) 11455570.87
時価総額 時価総額(百万ドル) 21.67280
売上高 売上高(百万ドル) 0.17598
企業価値(EV) 企業価値(EV)(百万ドル) 16.26598
当期純利益 当期純利益(百万ドル) -5.43327
決算概要 決算概要 BRIEF: For the six months ended 31 December 2017 Genetic Technologies Limited (ADR) revenues decreased 74% to A$98K. Net loss decreased 19% to A$3.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Selling and marketing expenses decrease of 45% to A$762K (expense) Impairment of intangible assets expense decrease from A$545K (expense) to A$0K.

 GENEのテクニカル分析


 GENEのニュース

   The Genetic Technologies Limited (GENE) had a good session last reading, didn’t it?  2023/02/22 15:00:00 US Post News
The share price of Genetic Technologies Limited (NASDAQ:GENE) fell to $1.25 per share on Tuesday from $1.35. While Genetic Technologies Limited has underperformed by -7.41%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GENE fell by -37.81%, with highs and lows ranging from $2.40 to $0.83, […]
   A Quick Glance At Genetic Technologies Limited (NASDAQ: GENE) Stock: It Is up 48.77% From Its 52-Week Low; YTD, It Is Up 74.19 Percent  2023/02/11 16:30:00 Marketing Sentinel
During the last session, Genetic Technologies Limited (NASDAQ:GENE)’s traded shares were 1.58 million, with the beta value of the company hitting 1.76. At the end of the trading day, the stock’s price was $1.62, reflecting an intraday loss of -8.47% or -$0.15. The 52-week high for the GENE share is $2.40, that puts it down … A Quick Glance At Genetic Technologies Limited (NASDAQ: GENE) Stock: It Is up 48.77% From Its 52-Week Low; YTD, It Is Up 74.19 Percent Read More »
   Becoming More Capital Intensive? Genetic Technologies Limited (NASDAQ:GENE) Is in green zone with the indicator reading 19.86%  2023/02/09 21:24:47 Stock Equity
(GENE) Constructed a change of 19.86% (Gain, ↑) in a total of its share price and finished it’s trading at 1.75. Genetic Technologies Limited, belongs to Healthcare sector and Diagnostics & Research industry. The … The post Becoming More Capital Intensive? Genetic Technologies Limited (NASDAQ:GENE) Is in green zone with the indicator reading 19.86% appeared first on Stocks Equity .
   Why Tivic Health Systems Are Trading Lower By 55%? Here Are Other Stocks Moving In Thursday''s Mid-Day Session  2023/02/09 17:50:58 Benzinga
Gainers Hempacco Co., Inc. (NASDAQ: HPCO ) rose 296% to $2.99 after declining 6% on Wednesday. Cardiovascular Systems, Inc. (NASDAQ: CSII ) shares jumped 48.6% to $19.78 following Q2 results. Abbott Laboratories agreed to acquire Cardiovascular Systems for $20 per share for an equity value of approximately $890 million. Wearable Devices Ltd. (NASDAQ: WLDS ) shares jumped 48.5% to $0.9273 after the company received approval from the Israel Innovation Authority for a $900,000 grant. SelectQuote, Inc. (NYSE: SLQT ) surged 40% to $2.1150. SelectQuote recently reported better-than-expected Q2 EPS and sales results and raised the lower end of its FY23 sales guidance above estimates. Blue Bird Corporation (NASDAQ: BLBD ) jumped 37.7% to $19.00 following upbeat quarterly sales. AppLovin Corporation (NASDAQ: APP ) shares surged 29.8% to $16.46 after the company issued strong Q1 guidance. Doma Holdings Inc. (NYSE: DOMA ) gained 24% to $0.6211. Doma Holdings is expected to report Q4 financial results after the market close on Tuesday, Feb. 28, 2023.
   Why Cardiovascular Systems Shares Are Trading Higher By 48%; Here Are 20 Stocks Moving Premarket  2023/02/09 13:54:43 Benzinga
Gainers Wearable Devices Ltd. (NASDAQ: WLDS ) shares rose 65% to $1.03 in pre-market trading after the company received approval from Israel Innovation Authority for $900,000 grant to finance further development of company''s manufacturing process for its Mudra Band. Hempacco Co., Inc. (NASDAQ: HPCO ) rose 56.4% to $1.1804 in pre-market trading after declining 6% on Wednesday. Cardiovascular Systems, Inc.. (NASDAQ: CSII ) rose 48.3% to $19.75 in pre-market trading following Q2 results. SeaStar Medical Holding Corporation (NASDAQ: ICU ) shares rose 40.7% to $6.76 in pre-market trading. SeaStar Medical received FDA approval to begin study with selective cytopheretic device to reduce hyperinflammation in adults with acute kidney injury. Genetic Technologies Limited (NASDAQ: GENE ) shares rose 27.4% to $1.86 in pre-market trading. Genetic Technologies announced new publication highlights geneType''s ability to detect breast cancer earlier and provide data for risk stratification. AppLovin Corporation (NASDAQ: APP ) rose 27.4% to $16.16 in pre-market trading after the company issued strong Q1 guidance.
   Genetic Technologies Limited (NASDAQ: GENE) Today’s Hot Stock  2023/01/02 16:00:00 Stocks Register
Genetic Technologies Limited (NASDAQ:GENE) traded at $0.93 at close of the session on Friday, 12/30/22, made a downward move of -3.12% on its previous day’s price. Looking at the stock we see that its previous close was $0.96 and the beta (5Y monthly) reads 1.22 with the day’s price range being $0.9101 – $0.99. In … Genetic Technologies Limited (NASDAQ: GENE) Today’s Hot Stock Read More »
   Thomas Park Names Gene Parker Chief Operating Officer  2022/06/01 17:05:00 Kwhen Finance
   ARGUS GT II Launched, Highlighting VOOPOO''s Innovation Story  2022/04/20 09:25:00 Kwhen Finance
   Genetic Technologies Ltd. - ADR Shares Fall 1.6% Below Previous 52-Week Low - Market Mover  2022/01/11 04:01:08 Kwhen Finance
Genetic Technologies Ltd. - ADR (GENE) shares closed 1.6% lower than its previous 52 week low, giving the company a market cap of $28M. The stock is currently flat year-to-date, down 54.1% over the past 12 months, and down 58.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 60.1% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -100.0% The company's stock price performance over the past 12 months lags the peer average by -3976.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Genetic Technologies Ltd. - ADR Shares Fall 1.6% Below Previous 52-Week Low - Market Mover  2022/01/11 04:01:08 Kwhen Finance
Genetic Technologies Ltd. - ADR (GENE) shares closed 1.6% lower than its previous 52 week low, giving the company a market cap of $28M. The stock is currently flat year-to-date, down 54.1% over the past 12 months, and down 58.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 60.1% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -100.0% The company's stock price performance over the past 12 months lags the peer average by -3976.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Genetic Technologies Ltd. - ADR Shares Approach 52-Week Low - Market Mover  2022/01/08 07:46:27 Kwhen Finance
Genetic Technologies Ltd. - ADR (GENE) shares closed today at 1.6% above its 52 week low of $1.85, giving the company a market cap of $29M. The stock is currently up 0.5% year-to-date, down 50.3% over the past 12 months, and down 59.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 47.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 2.6% lower than its 5-day moving average, 6.5% lower than its 20-day moving average, and 30.6% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -106.9% The company's stock price performance over the past 12 months lags the peer average by -1009.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Genetic Technologies Ltd. - ADR Shares Near 52-Week Low - Market Mover  2021/12/31 05:56:48 Kwhen Finance
Genetic Technologies Ltd. - ADR (GENE) shares closed today at 0.5% above its 52 week low of $1.87, giving the company a market cap of $29M. The stock is currently down 46.8% year-to-date, down 43.8% over the past 12 months, and down 55.7% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.1%. Trading Activity Trading volume this week was 25.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -318.6% The company's stock price performance over the past 12 months lags the peer average by -290.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Genetic Technologies Ltd. - ADR Shares Fall 0.8% Below Previous 52-Week Low - Market Mover  2021/12/30 03:29:39 Kwhen Finance
Genetic Technologies Ltd. - ADR (GENE) shares closed 0.8% lower than its previous 52 week low, giving the company a market cap of $30M. The stock is currently down 45.6% year-to-date, down 43.8% over the past 12 months, and down 54.6% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 26.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -312.3% The company's stock price performance over the past 12 months lags the peer average by -300.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Genetic Tech expects Q2 cash receipts of A$1.8M  2021/12/21 14:08:52 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ジェネティック・テクノロジ―ズ GENE Genetic Technologies Ltd)

 twitter  (公式ツイッターやCEOツイッターなど)